Quarterly report · Q1
2370.TEDINET S100SUKD
Period2023-10-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 32
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥248m | 2023-10-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥662m | 2022-10-01 → 2023-09-30 | Standalone | Net sales (5-year summary) |
| Revenue | ¥185m | 2022-10-01 → 2022-12-31 | Standalone | Net sales |
| Operating income | −¥294m | 2023-10-01 → 2023-12-31 | Standalone | Operating income |
| Operating income | −¥325m | 2022-10-01 → 2022-12-31 | Standalone | Operating income |
| Ordinary income | −¥292m | 2023-10-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.4bn | 2022-10-01 → 2023-09-30 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥324m | 2022-10-01 → 2022-12-31 | Standalone | Ordinary income |
| Profit before tax | −¥292m | 2023-10-01 → 2023-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥324m | 2022-10-01 → 2022-12-31 | Standalone | Income before income taxes |
| Net income | −¥293m | 2023-10-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | −¥1.4bn | 2022-10-01 → 2023-09-30 | Standalone | Net income loss (5-year summary) |
| Net income | −¥326m | 2022-10-01 → 2022-12-31 | Standalone | Profit loss |
| Total assets | ¥6.3bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥5.6bn | at 2023-09-30 | Standalone | Assets |
| Total assets | ¥5.5bn | at 2022-12-31 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥549m | at 2023-12-31 | Standalone | Liabilities |
| Total liabilities | ¥590m | at 2023-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥5.8bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥5.0bn | at 2023-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.0bn | at 2022-12-31 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.0bn | at 2023-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.4bn | at 2023-09-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥-1.2 | 2023-10-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.65 | 2022-10-01 → 2023-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.54 | 2022-10-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 91.3% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.2% | at 2023-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.8% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 253,510,757 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 232,160,757 | at 2023-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 211,730,423 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2023-12-31 | −¥147m |
| jpcrp040300-q1r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥56,000 |
| jpcrp040300-q1r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥56,000 |
| jpcrp040300-q1r_E05351-000Cellular And Tissue Based Product Businessreportable segment | segment profit | 2023-10-01 → 2023-12-31 | −¥115m |
| jpcrp040300-q1r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥248m |
| jpcrp040300-q1r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥248m |
| jpcrp040300-q1r_E05351-000Contract Cell Manufacturing Businessreportable segment | segment profit | 2023-10-01 → 2023-12-31 | −¥32m |
| —segment total | revenue | 2023-10-01 → 2023-12-31 | ¥248m |
| —segment total | revenue external | 2023-10-01 → 2023-12-31 | ¥248m |
| —segment total | segment profit | 2023-10-01 → 2023-12-31 | −¥147m |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2022-12-31 | −¥161m |
| jpcrp040300-q1r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥158,000 |
| jpcrp040300-q1r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥158,000 |
| jpcrp040300-q1r_E05351-000Cellular And Tissue Based Product Businessreportable segment | segment profit | 2022-10-01 → 2022-12-31 | −¥107m |
| jpcrp040300-q1r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥185m |
| jpcrp040300-q1r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥185m |
| jpcrp040300-q1r_E05351-000Contract Cell Manufacturing Businessreportable segment | segment profit | 2022-10-01 → 2022-12-31 | −¥57m |
| —segment total | revenue | 2022-10-01 → 2022-12-31 | ¥185m |
| —segment total | revenue external | 2022-10-01 → 2022-12-31 | ¥185m |
| —segment total | segment profit | 2022-10-01 → 2022-12-31 | −¥164m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 307
| Item | Context | Value | Unit |
|---|---|---|---|
| Footnotes regarding segment information table (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes revenue recognition quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |